See our roundup of today's AIM risers - see the full LSE winners & losers board here.

N4 Pharma (N4P) rises 30% to 6.35p a share 

Shares in N4 Pharma (N4P) , rose following the announcement of the results of its key research study on its Nuvec delivery system for vaccines and cancer treatments.

Its study revealed that Nuvec® provides a level of immune response comparable to existing delivery systems. This would allow the company to simplify and reduce the production cost of the final vaccine, it also showed no adverse toxicity.

Nigel Theobald, CEO of N4 Pharma commented: "The data validates the potential of Nuvec® to act as an alternative delivery system for the development of vaccines and cancer treatments but without the associated unwanted systemic side effects and with no signs of liver toxicity often seen using lipid nanoparticle systems.”

He added “Our next research study will focus on demonstrating the ability of Nuvec® to deliver an effective level of immunity using OVA, results of which will be available in first half of 2019.

Read more here & follow N4P here: 

Tom Energy (TOM) rises 20% to 9p a share

TomCo Energy (TOM)  is an oil shale exploration and development company focused on using innovative technology to unlock unconventional oil and gas resources.

It holds 2900 acres of land in the Uinta Basin of Utah, underlain by the Green River Shale Formation, including one block with a JORC Measured Resource of 126 million barrels of recoverable oil.

It acquired two key patents for an extraction technology, proven from a technical feasibility study, which showed the benefits of using a process involving the use of radio frequency in the extraction of oil & gas from oil shale

Read more here & follow TOM here: 

SalvaRx Group (SALV) rises to 12% to 65.25p a share

SalvaRx Group (SALV)  is a drug discovery and development company focused on immune-oncology, developing proprietary immune cell-activating cancer treatments.

It announced last week that preliminary data from a clinical study demonstrated that INT230-6, the Company's lead product candidate designed for direct intratumoral injection, was well tolerated in patients with advanced solid tumors.

Ian B. Walters, MD, Chief Medical Officer said: “This early data indicates that INT230-6 can be safely injected into several different types of superficial and deep tumors, and the vast majority of the active components stay inside the tumor,"

Read more here & follow SALV here: 

Concepta (CPT) rises 11% to 3.35p a share

Concepta (CPT)  is a UK healthcare company and developer of proprietary self-test platform ‘myLotus’ and emerging test products targeting the mobile health market. 

It announced today it received the CE-Mark certification for its myLotus products for women’s fertility, CE marking is a certification mark that indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area.

‘myLotus’ allows women to self-test to identify their optimal fertile days thereby improving their chances of naturally getting pregnant.

Matthew Walls, Chairman said “Novel self-test diagnostics for home-use is a highly regulated field of healthcare and this is a fabulous and eagerly awaited endorsement for the Company.” 

He added “Importantly the certification signals our drive to help improve the chances of women naturally getting pregnant and our preparations for the launch of myLotus in the UK and other CE-Mark territories. We will advise on the timing of the UK launch very shortly."

Read more here & follow CPT here: 

See all today's AIM Risers here